Table 2 Marginal effects of the associations between insurance-related ACA policy changes and HPV vaccine completion by sex and insurance type
ACA no cost sharing and dependent care provisions in 2010 | ACA insurance reforms in 2014 | |||||
|---|---|---|---|---|---|---|
Marginal effect (95% CI) | P-value | Wald test P-valuee | Marginal effect (95% CI) | P-value | Wald test P-valuee | |
3-dose HPV series completion within 12 monthsa,b | ||||||
Male | 0.05 | |||||
Private insurance | – | 0.051 (0.039–0.063) | < 0.01 | |||
Medicaid | – | 0.034 (0.017–0.050) | < 0.01 | |||
Female | 0.3 | 0.3 | ||||
Private insurance | 0.043 (0.036–0.061) | < 0.01 | 0.094 (0.082–0.107) | < 0.01 | ||
Medicaid | 0.057 (0.032–0.081) | < 0.01 | 0.085 (0.068–0.102) | < 0.01 | ||
3-dose HPV series completion within 18 monthsa,c | ||||||
Male | 0.03 | |||||
Private insurance | – | 0.060 (0.048–0.071) | < 0.01 | |||
Medicaid | – | 0.040 (0.022–0.058) | < 0.01 | |||
Female | 0.02 | 0.35 | ||||
Private insurance | 0.033 (0.014–0.052) | < 0.01 | 0.109 (0.097–0.121) | < 0.01 | ||
Medicaid | 0.069 (0.040–0.098) | < 0.01 | 0.100 (0.082–0.118) | < 0.01 | ||
2-dose HPV series completion within 12 monthsa,d | ||||||
Male | < 0.01 | |||||
Private insurance | – | 0.018 (0.006–0.029) | < 0.01 | |||
Medicaid | – | −0.026 (−0.046- -0.006) | 0.01 | |||
Female | 0.04 | 0.3 | ||||
Private insurance | 0.094 (0.055–0.134) | < 0.01 | 0.044 (0.032–0.056) | < 0.01 | ||
Medicaid | 0.025 (0.005–0.046) | 0.02 | 0.035 (0.015–0.054) | < 0.01 | ||